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Background: Peripheral venoarterial extracorporeal membranous oxygenation (ECMO) support is effective in
patients with cardiogenic shock or fatal arrhythmia due to fulminant myocarditis. The clinical courses of fulminant
myocarditis are still uncertain; therefore, it is difficult to determine the appropriate time for discontinuing ECMO or
converting to a ventricular assist device. The purpose of this study was to investigate the prognosis of patients with
fulminant myocarditis managed by ECMO.
Methods: Twenty-two consecutive patients with fulminant myocarditis managed by peripheral venoarterial ECMO
between 1999 and 2013 were enrolled.
Results: Survival to discharge was 59% (13 patients), and in-hospital mortality was 41% (9 patients). The age in the
survivor group was significantly lower than that in the non-survivor group (survivor group vs. non-survivor group;
36.5 ± 4.1 vs. 60.2 ± 5.0 years, p = 0.001). Although the ECMO support duration was similar between the groups
(181 ± 22 vs. 177 ± 31 h), the rate of complication related to ECMO was significantly lower in the survivor group
(15.3% vs. 66.6%, p = 0.02). When comparing the laboratory data during ECMO management between the groups,
the serum bilirubin level on day 7 was significantly lower in the survivor group (total: 4.6 ± 2.8 vs. 13.7 ± 10.8 mg/dL,
p = 0.014; direct: 2.2 ± 0.5 vs. 9.8 ± 4.5 mg/dL, p = 0.009).
Conclusions: Fulminant myocarditis is associated with high mortality rates despite ECMO. An older age and
complications related to ECMO are associated with poor prognosis.
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Fulminant myocarditis, which is defined as inflammation
of the myocardium, is a rapidly progressive life-threatening
disease accompanied by cardiogenic shock and heart
failure [1,2]. When conventional therapy cannot support
the circulatory condition, mechanical circulatory support is
required. Previous studies showed that mechanical circula-
tory support is effective in patients with cardiogenic shock* Correspondence: nakamuratomopon@gmail.com
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unless otherwise stated.due to fulminant myocarditis, and it was possible to
achieve an overall survival rate of 50%–70% [3-7]. Periph-
eral venoarterial extracorporeal membranous oxygenation
(ECMO) support can be introduced quickly and easily
without the need for a cardiovascular surgeon compared to
a ventricular assist device (VAD), and we applied periph-
eral venoarterial ECMO as a first line of mechanical circu-
latory support. However, we have to consider converting to
a VAD if cardiac function cannot be recovered even with
ECMO management. The aims of the present study were
to investigate the prognosis of patients with fulminant
myocarditis supported by ECMO and to clarify the limita-
tions of ECMO.ral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Patient population
In a retrospective chart review from 1999–2013, we identi-
fied 22 consecutive patients with fulminant myocarditis
managed by peripheral venoarterial ECMO at Jichi Medical
University Saitama Medical Center. The diagnosis of myo-
carditis was based on the following clinical findings: 1) a
recent medical history consistent with flu-like symptoms
such as respiratory or gastrointestinal symptoms; 2) ST-T
abnormalities detected by electrocardiography; 3) signifi-
cant changes in echocardiographic features; 4) positive
findings of inflammation (e.g., a fever of >38°C, increased
white blood cell count, and increased C-reactive protein
level); 5) absence of critical stenosis observed via coronary
angiography; 6) sudden onset of cardiogenic shock; and 7)
requiring ECMO for prolonged cardiogenic shock. The
pathological etiology of fulminant myocarditis was not
included in these criteria. The induction criteria for ECMO
were cardiogenic shock refractory to inotropic agents,
intra-aortic balloon pumping (IABP), or life-threatening
arrhythmia.The device and management
The peripheral venoarterial ECMO system consists
of a centrifugal pump, a polypropylene hollow-fiber
membrane oxygenator, and a heparin-coated circuit
(Terumo Inc., Tokyo, Japan). We used a 15-French (Fr)
arterial cannula with a length of 15 cm and a 21-Fr
venous cannula with a length of 50 cm, both of which
were inserted via the femoral vessels by using the Seldin-
ger technique. Mechanical circulation was established with
venous blood drainage from the right atrium and arterial
blood return to the iliac artery.
The management and weaning of ECMO were per-
formed according to the previously described guideline
[7]. Low-dose heparin was continuously administrated
to maintain an activated clotting time of 150–200 s. To
prevent poor venous drainage, right atrium pressure
was maintained (>10 mm Hg) with adequate fluid ad-
ministration, and blood transfusion was performed to
maintain a hemoglobin level of >10 g/dL and a platelet
level of >50,000/μL. A distal perfusion catheter into the
superficial femoral artery or dorsal pedis artery was
required to prevent distal leg ischemia.
The initial flow rate was 3.0–3.5 L/min to assist recov-
ery from peripheral circulatory failure. In all patients,
ECMO was introduced in the catheter laboratory, and
the initial flow rate and rotation speed of ECMO were
appropriate. According to the indicators of peripheral
circulatory failure (e.g., arterial blood gas analysis, mixed
venous oxygen saturation, lactic acid, and urinary
output), the flow rate of ECMO was decreased. When
the flow rate reached 1.0 L/min, the patients could beweaned off ECMO if their vital signs and the abovemen-
tioned indicators were acceptable.
Data collection and statistical analysis
Blood samples were obtained every 4 h until the peak cre-
atinine kinase (CK) and CK-MB levels were determined,
and thereafter, they were collected every 24 h until the pa-
tients recovered or died. We have investigated the ECMO-
related complications including leg ischemia, stroke, major
bleeding, and multiple organ failure (MOF). The definition
of major bleeding was the uncontrolled hemorrhage
requiring the additional transfusion at vascular access
sites, retroperitoneal space, or gastrointestinal tract.
Data were expressed as the frequency and percentage
for categorical variables and the mean ± standard deviation
for continuous variables. We compared data between the
survivors and non-survivors. Continuous data were ana-
lyzed by using the Student t-test or the Mann–Whitney
U-test. Categorical data were analyzed by using the Fisher
exact test. For all analyses, a two-tailed P value of <0.05
was considered statistically significant. All statistical ana-
lyses were performed by using the SPSS statistical soft-
ware, version 13.0 for Windows (SPSS, Chicago, IL, USA).
All subjects enrolled in this research have given their
informed consent which has been approved by my institu-
tional committee on human research, and this protocol
has been found acceptable by them.
Results
Between 1999 and 2013, we included 22 patients with
fulminant myocarditis who were managed with ECMO.
Thirteen patients (59%) were discharged from the hos-
pital. One of these 13 patients underwent heart trans-
plantation after converting to the left VAD, and she was
discharged in excellent condition. Table 1 shows the pa-
tients’ baseline clinical characteristics. On admission, the
circulatory condition and laboratory data were similar
between the survivor group and the non-survivor group.
The average age of those in the survivor group was sig-
nificantly lower than that in the non-survivor group
(36.5 ± 4.1 vs. 60.2 ± 5.0 years, p = 0.001).
Table 2 compares the treatment and ECMO manage-
ment between the groups. The use of steroid, IABP, and
continuous hemodiafiltration was similar between the
groups. Although the ECMO duration was similar be-
tween the groups (survivor group vs. non-survivor
group; 181 ± 22 vs. 177 ± 31 h, respectively; p = 0.15), the
rate of complications related to ECMO was significantly
lower in the survivor group (15.3% vs. 66.6%, p = 0.02).
Complications such as major bleeding and MOF were
more common in the non-survivor group.
Figure 1 shows the serial changes in the laboratory data,
including the white blood cell count and levels of glutamic
oxaloacetic transaminase, glutamic pyruvic transaminase,






Steroid therapy 7 (54%) 2 (22%) 0.15
IABP use 13 (100%) 8 (89%) 0.41
CHDF use 2 (15%) 3 (33%) 0.32
Total operating time of ECMO, h 181 ± 22 177 ± 31 0.15
Complications associated with ECMO
Total 3 (23%) 8 (89%) 0.004
Leg ischemia 0 (0%) 2 (22%) 0.16
Stroke 0 (0%) 2 (22%) 0.16
Bleeding 2 (15%) 6 (67%) 0.02
Multiple organ failure 2 (15%) 6 (67%) 0.02
Data are presented as the mean ± standard deviation or as the number of
patients (%).
IABP intra-aortic balloon pump, CHDF continuous hemodiafiltration.
Table 1 Baseline characteristics of patients with







Age, years 36.5 ± 14.7 60.2 ± 14.9 0.001
Male sex 6 (46%) 4 (44%) 0.64
Systolic BP, mm Hg 84.5 ± 21.7 81.4 ± 27.3 0.78
Heart rate, bpm 110.0 ± 33.3 92.0 ± 26.1 0.22
Presence of pulseless
VT or Vf
9 (69%) 6 (67%) 0.90
LVDd, mm 46.0 ± 7.7 44.0 ± 5.4 0.62
LVDs, mm 40.7 ± 7.3 36.4 ± 4.2 0.25
LVEF, % 22.9 ± 8.5 23.6 ± 12.6 0.88
Laboratory data
on admission
WBC (/μL) 10,213.9 ± 5,431.6 11,937.8 ± 9,399.0 0.59
GOT (IU/L) 768.6 ± 864.1 1,599.8 ± 2,759.7 0.40
GPT (IU/L) 540.6 ± 726.9 1,044.2 ± 1,882.0 0.46
LDH (IU/L) 2,187.9 ± 2,198.0 2,815.1 ± 4,245.1 0.65
Total-Bil (mg/dL) 0.72 ± 0.29 0.85 ± 0.49 0.46
Direct-Bil (mg/dL) 0.28 ± 0.11 0.37 ± 0.31 0.36
BUN (mg/dL) 26.7 ± 12.4 38.9 ± 29.0 0.26
Creatinine (mg/dL) 1.47 ± 0.76 1.48 ± 0.98 0.99
Max. CK (IU/L) 3,090.2 ± 4,416.1 3,148.0 ± 4,456.2 0.98
Max. CK-MB (IU/L) 154.9 ± 279.8 113.2 ± 70.1 0.67
Data are presented as the mean ± standard deviation or as the number of
patients (%).
BP blood pressure, VT ventricular tachycardia, Vf ventricular fibrillation, LVDd
left ventricular end-diastolic dimension, LVDs left ventricular end-systolic
dimension, LVEF left ventricular ejection fraction, WBC white blood cell, GOT
glutamic oxaloacetic transaminase, GPT glutamic pyruvic transaminase, LDH
lactate dehydrogenase, Bil bilirubin, BUN blood urea nitrogen, Max. maximum,
CK creatine kinase.
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urea nitrogen, and creatinine, during ECMO management.
The serum levels of total bilirubin and direct bilirubin on
day 7 were significantly lower in the survivor group (total
bilirubin: 4.6 ± 2.8 vs. 13.7 ± 10.8 mg/dL, p = 0.014; direct
bilirubin: 2.2 ± 0.5 vs. 9.8 ± 4.5 mg/dL, p = 0.009).
Discussion
Fulminant myocarditis, which is characterized by exten-
sive inflammatory infiltration and numerous foci of myo-
cyte necrosis, is a rapidly progressive life-threatening
disease, and survival rates have been reported as 50%–70%
[1-7]. Our study found that the survival rate was 59% in
patients with fulminant myocarditis managed by periph-
eral venoarterial ECMO. And elderly patients who might
be in vulnerable conditions were associated with poor
prognosis. Although the baseline characteristics except for
age were similar between the survivor group and the non-
survivor group, it was expected that the reserve of end-
organ function is low in elderly patients. Considering that
we do not treat pediatric patients with fulminant myocar-
ditis and we excluded adult patients who did not require
ECMO, our findings are acceptable.
Cardiopulmonary support systems play an important
role in patients who develop cardiogenic shock or fatal
arrhythmia. Pages et al. [8] reported that peripheral
venoarterial ECMO was as efficient as bi-VAD in patients
with fulminant myocarditis related to cardiogenic shock,
because it facilitated renal and hepatic recovery. Acker
et al. [4] suggested that the survival rates in cases by using
peripheral venoarterial ECMO were higher than in cases
by using VAD. When compared to VAD, peripheral
venoarterial ECMO could be introduced quickly and easily
to prevent hemodynamic deterioration. In Japan, a thera-
peutic guideline by Aoyama et al. [7] recommended that
ECMO should be instituted if the patient with fulminant
myocarditis does not recover from circulatory failure des-
pite the use of cardiotonic or vasopressor drugs and IABP
treatment. However, continued use of ECMO causes many
problems, including bleeding, hemolysis, leg ischemia, or
MOF, and ECMO is not suitable for long-term support.
Previous studies investigating patients with acute coronary
syndrome requiring ECMO reported that the complica-
tions related to ECMO were associated with poor progno-
sis [9,10]. A study in patients with fulminant myocarditis
by Aoyama et al., as previously described, reported that
leg ischemia and MOF related to ECMO were poor prog-
nostic factors [7]. Our study findings were similar consid-
ering the incidence rate of ECMO-related complications;
in particular, bleeding events and MOF were significantly
greater in the non-survivor group. This suggests that we
should pay careful attention to prevent complications
related to ECMO in an effort to improve the prognosis of
fulminant myocarditis.
Figure 1 (See legend on next page.)
Nakamura et al. Journal of Intensive Care  (2015) 3:5 Page 4 of 5
(See figure on previous page.)
Figure 1 Serial changes of markers during extracorporeal membranous oxygenation support. (a) White blood cell (WBC), (b) glutamic
oxaloacetic transaminase (GOT), (c) glutamic pyruvic transaminase (GPT), (d) lactate dehydrogenase (LDH), (e) total bilirubin, (f) direct bilirubin, (g)
blood urea nitrogen (BUN), and (h) creatinine. There were no significant differences between the survivor group and non-survivor group, except for in
the serum bilirubin levels. The serum total and direct bilirubin levels on day 7 in the survivor group were significantly lower compared with those on
day 7 in the non-survivor group (total bilirubin: 4.6 ± 2.8 vs. 13.7 ± 10.8 mg/dL, p = 0.014; direct bilirubin: 2.2 ± 0.5 vs. 9.8 ± 4.5 mg/dL, p = 0.009).
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that can occur during ECMO management. Liver failure
is especially difficult to treat, even though cardiopulmo-
nary failure and renal failure can be supported by VAD
and hemodialysis. Peek et al. [11] reported that a high
bilirubin level in patients managed by ECMO was asso-
ciated with high mortality. Unosawa et al. [12] suggested
that ECMO should be converted to VAD before the total
bilirubin level increases to 3.0 mg/dL. Imamura et al.
[13] reported that bilirubin or creatinine levels adjusted
by age can be predictors of reversibility of end-organ
dysfunction in patients with advanced stage heart failure.
In our study, the serum bilirubin levels in the non-
survivor group significantly increased during ECMO
management, which might reflect the progression of
MOF. According to these findings, the serum bilirubin
level might help us to manage the patients with fulmin-
ant myocarditis during ECMO. Therefore, we have to
consider this when converting peripheral venoarterial
ECMO to VAD in patients whose cardiac functions are
not improved and in those whose serum bilirubin levels
have suddenly increased after ECMO was introduced.
This study has several limitations. First, it was a retro-
spective study at a single center, and the number of sub-
jects is small. Second, we excluded pediatric patients,
and the minimum age in our study was 14 years old.
Thus, it is unclear whether our conclusions can be ap-
plied to pediatric patients. Third, since the study period
was 1999–2014, improvement in ECMO management
may affect the prognoses. Fourth, in our hospital, only
one patient in the survivor group was converted from
peripheral venoarterial ECMO to VAD because of ful-
minant myocarditis; therefore, we have to admit a lack
of experience in using VAD for treating fulminant myo-
carditis. Thus, the prognosis after conversion to VAD is
unknown.
Conclusions
In conclusion, the mortality of fulminant myocarditis
with hemodynamic collapse is still high even under
ECMO management. We should pay careful attention to
elderly patients and the complications related to ECMO,
which are both associated with poor prognosis.
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